Molbio Diagnostics Eyes ₹940 Crore Through IPO for Growth and Expansion

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is set to raise ₹940 crore through its upcoming initial public offering (IPO). The company aims to secure ₹200 crore via a fresh issue to bolster its capital expenditures, while an additional ₹740 crore will be raised through an offer for sale, effectively reducing the promoter's stake from 46.6% to 43%.

Operating six manufacturing sites across India, Molbio Diagnostics caters to over 90 countries, including government health programs, diagnostic labs, hospitals, and international healthcare organizations. The company has experienced significant revenue growth, primarily driven by its tuberculosis diagnostic test kits.

Strategic Expansion and Product Offerings

Founded in 2000, Molbio has focused on the research, development, and manufacturing of diagnostic solutions for both infectious and non-communicable diseases. Its flagship product, the 'Truenat' platform, is a portable diagnostic system designed for use in resource-limited settings, providing accurate test results within an hour. The company offers molecular testing solutions for over 30 diseases through 43 diagnostic assays and has expanded into radiology, digital pathology, and breast health screening solutions via subsidiaries and strategic partnerships.

Government and international aid agencies account for over 80% of Molbio's revenue, underscoring its significant reliance on these entities. Notably, 74% of the company's revenue is derived from the sale of test kits, with tuberculosis diagnostic kits contributing 70% to this segment.

Financial Performance and Market Position

Molbio Diagnostics has reported robust financial growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore from FY24 to FY26. During the same period, net profit surged by 40.2% to ₹164.1 crore, and operating profit before interest, tax, depreciation, and amortization (EBITDA) rose by 33.2% to ₹328.2 crore. The EBITDA margin also improved, reaching 22.6% in FY26 from 22% in FY24.

In FY26 alone, the company saw a year-on-year revenue increase of 41.7%, with EBITDA rising by 27.9% and net profit growing by 18.4%. Despite the lack of directly comparable listed peers in India, Molbio's valuation demands a price-earnings (P/E) multiple of up to 57, aligning it with other healthcare diagnostics and medical device firms such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples between 54 and 81.

Investment Considerations

The upcoming IPO presents an opportunity for high-risk investors seeking long-term growth potential. With its proven track record in the diagnostics field and strategic plans for expansion, Molbio Diagnostics is well-positioned to capitalize on its strengths in the global market. However, potential investors should consider the company's customer concentration and reliance on government and international aid agencies when evaluating their investment decision.